Skip to search formSkip to main contentSkip to account menu

ALT-803

Known as: IL-15N72D/IL-15Ra-Fc, IL-15N72D:IL-15RaSu/Fc Fusion Complex, Superagonist Interleukin-15:Interleukin-15 Receptor alphaSu/Fc Fusion Complex ALT-803 
A fusion protein complex composed of a mutated form of the cytokine interleukin (IL)-15 (IL-15N72D) and a soluble, dimeric IL-15 receptor alpha (IL… 
National Institutes of Health

Related topics

Related topics

2 relations
NCIt Antineoplastic Agent Terminology

Broader (1)

Proteins

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2019
Review
2019
Adaptive NK cell responses in HIV/SIV infections: A roadmap to cell‐based therapeutics?
NK cells play a critical role in antiviral and antitumor responses. Although current NK cell immune therapies have focused… 
Review
2019
Review
2019
Immunogenomic Analysis of Exceptional Responder to ALT-803 (IL-15 Analogue) in BCG Unresponsive Nonmuscle Invasive Bladder Cancer: A Case Series and Review of the Literature
Supplemental Digital Content is available in the text. The clinical validity and utility of complex biomarkers have not been… 
2018
2018
Phase Ib trial of ALT-803, an IL-15 superagonist, plus BCG for the treatment of BCG-naïve patients with non-muscle-invasive bladder cancer.
510Background: The current standard of care for patients with high risk NMIBC is a TURBT or biopsy followed by a 6-week induction… 
2018
2018
A multicenter clinical trial of intravesical BCG in combination with ALT-803 in patients with BCG-unresponsive non-muscle invasive bladder cancer.
TPS544Background: BCG unresponsive NMIBC includes patients with persistent high-grade disease or recurrence within 6 months of… 
2017
2017
Intravesical ALT-803 for BCG-unresponsive Bladder Cancer – A Case Report
2017
2017
The IL15 Superagonist Complex ALT-803 Potently Enhances the Proliferative Capacity and Activity of in Vitro Expanded Natural Killer Cells
Introduction We previously reported on the treatment of 8 relapsing high-risk multiple myeloma (HRMM) patients with ex vivo… 
2016
2016
Phase Ib trial of ALT-803, an IL-15 superagonist, plus Bacillus Calmette Guerin (BCG) for the treatment of patients with BCG-naïve non-muscle-invasive bladder cancer (NMIBC).
470 Background: Novel agents are necessary to treat NMIBC to avoid recurrence and progression. This phase Ib clinical trial… 
2015
2015
'First-in-human' phase I dose escalation trial of IL-15N72D/IL-15Rα-Fc superagonist complex (ALT-803) demonstrates immune activation with anti-tumor activity in patients with relapsed hematological…
Disease-free survival after allogeneic transplantation for hematological malignancies may be enhanced with post-transplant… 
2015
2015
Combination therapy of an IL-15 superagonist complex, ALT-803, and a tumor targeting monoclonal antibody promotes direct antitumor activity and protective vaccinal effect in a syngenic mouse melanoma…
Cytokine-based and antibody-targeted immunotherapies have both been important approaches in the treatment of malignant cancers… 
2009
2009
Synthetic glucagon antagonists and partial agonists.
This paper reports the synthesis and the biological activities of six new glucagon analogues. In these compounds N-terminal… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)